Loading…

Prostate Volume Is Strongest Predictor of Cancer Diagnosis at Transrectal Ultrasound-Guided Prostate Biopsy with Prostate-Specific Antigen Values Between 2.0 and 9.0 ng/mL

Objectives Data have suggested benign prostatic hyperplasia, and not cancer, as the major reason for elevated prostate-specific antigen (PSA) values between 2.0 and 9.0 ng/mL. If this hypothesis were correct, within these ranges, a smaller prostate volume would be a stronger predictor of cancer than...

Full description

Saved in:
Bibliographic Details
Published in:Urology (Ridgewood, N.J.) N.J.), 2007, Vol.69 (1), p.103-107
Main Authors: Al-Azab, Rami, Toi, Ants, Lockwood, Gina, Kulkarni, Girish S, Fleshner, Neil
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c448t-d25a430e0d83c355f93f701afda92293f230595d6fc1d764075a84fe63339f513
cites cdi_FETCH-LOGICAL-c448t-d25a430e0d83c355f93f701afda92293f230595d6fc1d764075a84fe63339f513
container_end_page 107
container_issue 1
container_start_page 103
container_title Urology (Ridgewood, N.J.)
container_volume 69
creator Al-Azab, Rami
Toi, Ants
Lockwood, Gina
Kulkarni, Girish S
Fleshner, Neil
description Objectives Data have suggested benign prostatic hyperplasia, and not cancer, as the major reason for elevated prostate-specific antigen (PSA) values between 2.0 and 9.0 ng/mL. If this hypothesis were correct, within these ranges, a smaller prostate volume would be a stronger predictor of cancer than the PSA level itself (the relative contribution from cancer is greater in smaller glands). Methods We examined our institutional data set of transrectal ultrasound-guided procedures from 2000 to 2003. We studied patients who presented for their first prostate biopsy with a PSA level of 2.0 to 9.0 ng/mL. The indications for biopsy were elevated age-specific PSA level or abnormal digital rectal examination findings. Other covariates included patient age, abnormal transrectal ultrasound findings, transrectal ultrasound volume, and biopsy sampling scheme. Univariate analyses were used to assess the association between each variable and cancer diagnosis. Multivariate logistic regression modeling was then used to determine the adjusted risk factors for cancer at biopsy. Results On univariate analyses, all measured covariates were predictive of cancer. On multivariate modeling, the significant risk factors (in order of strength) for positive biopsy findings were smaller prostate volume (odds ratio [OR] 0.26, P
doi_str_mv 10.1016/j.urology.2006.09.041
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68976176</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090429506021650</els_id><sourcerecordid>68976176</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-d25a430e0d83c355f93f701afda92293f230595d6fc1d764075a84fe63339f513</originalsourceid><addsrcrecordid>eNqFkstuEzEUhkcIREPhEUDewG6mx56xZ7wBtQFKpUhUStutZXwJDhM7tT1UeSZeEkeJWokNK-tY37n9_6mqtxgaDJidrZsphjGsdg0BYA3wBjr8rJphSvqac06fVzMADnVHOD2pXqW0hgIy1r-sTnBPemBkmFV_rmNIWWaD7sI4bQy6SmiZY_ArkzK6jkY7lUNEwaK59MpE9NnJlQ_JJSQzuonSp2hUliO6HXOUKUxe15eT00ajx9oXLmzTDj24_PPxs15ujXLWKXTus1sZj-7kOJmELkx-MCUkDSDpNSqbIb862yxeVy-sHJN5c3xPq9uvX27m3-rF98ur-fmiVl035FoTKrsWDOihVS2llre2ByytlpyQEpAWKKeaWYV1zzroqRw6a1jbttxS3J5WHw51tzHcl4my2LikzDhKb8KUBBt4z3DPCkgPoCo7FRms2Ea3kXEnMIi9S2Itji6JvUsCuCgulbx3xwbTj43RT1lHWwrw_gjIpORoi8rKpSduoBgXWwv36cCZIsdvZ6JIyplik3Z7U4QO7r-jfPynghqdd6XpL7MzaR2m6IvWAotEBIjl_qT2FwUMCGYU2r8KLclV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68976176</pqid></control><display><type>article</type><title>Prostate Volume Is Strongest Predictor of Cancer Diagnosis at Transrectal Ultrasound-Guided Prostate Biopsy with Prostate-Specific Antigen Values Between 2.0 and 9.0 ng/mL</title><source>ScienceDirect Freedom Collection</source><creator>Al-Azab, Rami ; Toi, Ants ; Lockwood, Gina ; Kulkarni, Girish S ; Fleshner, Neil</creator><creatorcontrib>Al-Azab, Rami ; Toi, Ants ; Lockwood, Gina ; Kulkarni, Girish S ; Fleshner, Neil</creatorcontrib><description>Objectives Data have suggested benign prostatic hyperplasia, and not cancer, as the major reason for elevated prostate-specific antigen (PSA) values between 2.0 and 9.0 ng/mL. If this hypothesis were correct, within these ranges, a smaller prostate volume would be a stronger predictor of cancer than the PSA level itself (the relative contribution from cancer is greater in smaller glands). Methods We examined our institutional data set of transrectal ultrasound-guided procedures from 2000 to 2003. We studied patients who presented for their first prostate biopsy with a PSA level of 2.0 to 9.0 ng/mL. The indications for biopsy were elevated age-specific PSA level or abnormal digital rectal examination findings. Other covariates included patient age, abnormal transrectal ultrasound findings, transrectal ultrasound volume, and biopsy sampling scheme. Univariate analyses were used to assess the association between each variable and cancer diagnosis. Multivariate logistic regression modeling was then used to determine the adjusted risk factors for cancer at biopsy. Results On univariate analyses, all measured covariates were predictive of cancer. On multivariate modeling, the significant risk factors (in order of strength) for positive biopsy findings were smaller prostate volume (odds ratio [OR] 0.26, P &lt;0.001), increasing age (OR 1.72, P &lt;0.001), increasing PSA (OR 1.64, P &lt;0.001), and the presence of hypoechoic lesions (OR 2.42, P &lt;0.001). Conclusions When the PSA level is in the 2.0 to 9.0 ng/mL range, a smaller prostate volume is the strongest predictor of cancer detection. These data support previous studies suggesting the amount of benign prostatic hyperplasia, and not cancer, as the major factor responsible for elevated PSA.</description><identifier>ISSN: 0090-4295</identifier><identifier>EISSN: 1527-9995</identifier><identifier>DOI: 10.1016/j.urology.2006.09.041</identifier><identifier>PMID: 17270628</identifier><identifier>CODEN: URGYAZ</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Biological and medical sciences ; Biopsy - methods ; Humans ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Organ Size ; Predictive Value of Tests ; Prostate - pathology ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - diagnostic imaging ; Prostatic Neoplasms - pathology ; Rectum ; Ultrasonography ; Urology</subject><ispartof>Urology (Ridgewood, N.J.), 2007, Vol.69 (1), p.103-107</ispartof><rights>Elsevier Inc.</rights><rights>2007 Elsevier Inc.</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-d25a430e0d83c355f93f701afda92293f230595d6fc1d764075a84fe63339f513</citedby><cites>FETCH-LOGICAL-c448t-d25a430e0d83c355f93f701afda92293f230595d6fc1d764075a84fe63339f513</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18511295$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17270628$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al-Azab, Rami</creatorcontrib><creatorcontrib>Toi, Ants</creatorcontrib><creatorcontrib>Lockwood, Gina</creatorcontrib><creatorcontrib>Kulkarni, Girish S</creatorcontrib><creatorcontrib>Fleshner, Neil</creatorcontrib><title>Prostate Volume Is Strongest Predictor of Cancer Diagnosis at Transrectal Ultrasound-Guided Prostate Biopsy with Prostate-Specific Antigen Values Between 2.0 and 9.0 ng/mL</title><title>Urology (Ridgewood, N.J.)</title><addtitle>Urology</addtitle><description>Objectives Data have suggested benign prostatic hyperplasia, and not cancer, as the major reason for elevated prostate-specific antigen (PSA) values between 2.0 and 9.0 ng/mL. If this hypothesis were correct, within these ranges, a smaller prostate volume would be a stronger predictor of cancer than the PSA level itself (the relative contribution from cancer is greater in smaller glands). Methods We examined our institutional data set of transrectal ultrasound-guided procedures from 2000 to 2003. We studied patients who presented for their first prostate biopsy with a PSA level of 2.0 to 9.0 ng/mL. The indications for biopsy were elevated age-specific PSA level or abnormal digital rectal examination findings. Other covariates included patient age, abnormal transrectal ultrasound findings, transrectal ultrasound volume, and biopsy sampling scheme. Univariate analyses were used to assess the association between each variable and cancer diagnosis. Multivariate logistic regression modeling was then used to determine the adjusted risk factors for cancer at biopsy. Results On univariate analyses, all measured covariates were predictive of cancer. On multivariate modeling, the significant risk factors (in order of strength) for positive biopsy findings were smaller prostate volume (odds ratio [OR] 0.26, P &lt;0.001), increasing age (OR 1.72, P &lt;0.001), increasing PSA (OR 1.64, P &lt;0.001), and the presence of hypoechoic lesions (OR 2.42, P &lt;0.001). Conclusions When the PSA level is in the 2.0 to 9.0 ng/mL range, a smaller prostate volume is the strongest predictor of cancer detection. These data support previous studies suggesting the amount of benign prostatic hyperplasia, and not cancer, as the major factor responsible for elevated PSA.</description><subject>Biological and medical sciences</subject><subject>Biopsy - methods</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Organ Size</subject><subject>Predictive Value of Tests</subject><subject>Prostate - pathology</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - diagnostic imaging</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Rectum</subject><subject>Ultrasonography</subject><subject>Urology</subject><issn>0090-4295</issn><issn>1527-9995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNqFkstuEzEUhkcIREPhEUDewG6mx56xZ7wBtQFKpUhUStutZXwJDhM7tT1UeSZeEkeJWokNK-tY37n9_6mqtxgaDJidrZsphjGsdg0BYA3wBjr8rJphSvqac06fVzMADnVHOD2pXqW0hgIy1r-sTnBPemBkmFV_rmNIWWaD7sI4bQy6SmiZY_ArkzK6jkY7lUNEwaK59MpE9NnJlQ_JJSQzuonSp2hUliO6HXOUKUxe15eT00ajx9oXLmzTDj24_PPxs15ujXLWKXTus1sZj-7kOJmELkx-MCUkDSDpNSqbIb862yxeVy-sHJN5c3xPq9uvX27m3-rF98ur-fmiVl035FoTKrsWDOihVS2llre2ByytlpyQEpAWKKeaWYV1zzroqRw6a1jbttxS3J5WHw51tzHcl4my2LikzDhKb8KUBBt4z3DPCkgPoCo7FRms2Ea3kXEnMIi9S2Itji6JvUsCuCgulbx3xwbTj43RT1lHWwrw_gjIpORoi8rKpSduoBgXWwv36cCZIsdvZ6JIyplik3Z7U4QO7r-jfPynghqdd6XpL7MzaR2m6IvWAotEBIjl_qT2FwUMCGYU2r8KLclV</recordid><startdate>2007</startdate><enddate>2007</enddate><creator>Al-Azab, Rami</creator><creator>Toi, Ants</creator><creator>Lockwood, Gina</creator><creator>Kulkarni, Girish S</creator><creator>Fleshner, Neil</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2007</creationdate><title>Prostate Volume Is Strongest Predictor of Cancer Diagnosis at Transrectal Ultrasound-Guided Prostate Biopsy with Prostate-Specific Antigen Values Between 2.0 and 9.0 ng/mL</title><author>Al-Azab, Rami ; Toi, Ants ; Lockwood, Gina ; Kulkarni, Girish S ; Fleshner, Neil</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-d25a430e0d83c355f93f701afda92293f230595d6fc1d764075a84fe63339f513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Biological and medical sciences</topic><topic>Biopsy - methods</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Organ Size</topic><topic>Predictive Value of Tests</topic><topic>Prostate - pathology</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - diagnostic imaging</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Rectum</topic><topic>Ultrasonography</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al-Azab, Rami</creatorcontrib><creatorcontrib>Toi, Ants</creatorcontrib><creatorcontrib>Lockwood, Gina</creatorcontrib><creatorcontrib>Kulkarni, Girish S</creatorcontrib><creatorcontrib>Fleshner, Neil</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urology (Ridgewood, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al-Azab, Rami</au><au>Toi, Ants</au><au>Lockwood, Gina</au><au>Kulkarni, Girish S</au><au>Fleshner, Neil</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prostate Volume Is Strongest Predictor of Cancer Diagnosis at Transrectal Ultrasound-Guided Prostate Biopsy with Prostate-Specific Antigen Values Between 2.0 and 9.0 ng/mL</atitle><jtitle>Urology (Ridgewood, N.J.)</jtitle><addtitle>Urology</addtitle><date>2007</date><risdate>2007</risdate><volume>69</volume><issue>1</issue><spage>103</spage><epage>107</epage><pages>103-107</pages><issn>0090-4295</issn><eissn>1527-9995</eissn><coden>URGYAZ</coden><abstract>Objectives Data have suggested benign prostatic hyperplasia, and not cancer, as the major reason for elevated prostate-specific antigen (PSA) values between 2.0 and 9.0 ng/mL. If this hypothesis were correct, within these ranges, a smaller prostate volume would be a stronger predictor of cancer than the PSA level itself (the relative contribution from cancer is greater in smaller glands). Methods We examined our institutional data set of transrectal ultrasound-guided procedures from 2000 to 2003. We studied patients who presented for their first prostate biopsy with a PSA level of 2.0 to 9.0 ng/mL. The indications for biopsy were elevated age-specific PSA level or abnormal digital rectal examination findings. Other covariates included patient age, abnormal transrectal ultrasound findings, transrectal ultrasound volume, and biopsy sampling scheme. Univariate analyses were used to assess the association between each variable and cancer diagnosis. Multivariate logistic regression modeling was then used to determine the adjusted risk factors for cancer at biopsy. Results On univariate analyses, all measured covariates were predictive of cancer. On multivariate modeling, the significant risk factors (in order of strength) for positive biopsy findings were smaller prostate volume (odds ratio [OR] 0.26, P &lt;0.001), increasing age (OR 1.72, P &lt;0.001), increasing PSA (OR 1.64, P &lt;0.001), and the presence of hypoechoic lesions (OR 2.42, P &lt;0.001). Conclusions When the PSA level is in the 2.0 to 9.0 ng/mL range, a smaller prostate volume is the strongest predictor of cancer detection. These data support previous studies suggesting the amount of benign prostatic hyperplasia, and not cancer, as the major factor responsible for elevated PSA.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>17270628</pmid><doi>10.1016/j.urology.2006.09.041</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0090-4295
ispartof Urology (Ridgewood, N.J.), 2007, Vol.69 (1), p.103-107
issn 0090-4295
1527-9995
language eng
recordid cdi_proquest_miscellaneous_68976176
source ScienceDirect Freedom Collection
subjects Biological and medical sciences
Biopsy - methods
Humans
Male
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
Organ Size
Predictive Value of Tests
Prostate - pathology
Prostate-Specific Antigen - blood
Prostatic Neoplasms - blood
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - diagnostic imaging
Prostatic Neoplasms - pathology
Rectum
Ultrasonography
Urology
title Prostate Volume Is Strongest Predictor of Cancer Diagnosis at Transrectal Ultrasound-Guided Prostate Biopsy with Prostate-Specific Antigen Values Between 2.0 and 9.0 ng/mL
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T23%3A55%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prostate%20Volume%20Is%20Strongest%20Predictor%20of%20Cancer%20Diagnosis%20at%20Transrectal%20Ultrasound-Guided%20Prostate%20Biopsy%20with%20Prostate-Specific%20Antigen%20Values%20Between%202.0%20and%209.0%20ng/mL&rft.jtitle=Urology%20(Ridgewood,%20N.J.)&rft.au=Al-Azab,%20Rami&rft.date=2007&rft.volume=69&rft.issue=1&rft.spage=103&rft.epage=107&rft.pages=103-107&rft.issn=0090-4295&rft.eissn=1527-9995&rft.coden=URGYAZ&rft_id=info:doi/10.1016/j.urology.2006.09.041&rft_dat=%3Cproquest_cross%3E68976176%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c448t-d25a430e0d83c355f93f701afda92293f230595d6fc1d764075a84fe63339f513%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=68976176&rft_id=info:pmid/17270628&rfr_iscdi=true